{"id":1369,"date":"2016-10-24T17:50:25","date_gmt":"2016-10-24T12:20:25","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1369"},"modified":"2025-05-05T14:34:48","modified_gmt":"2025-05-05T09:04:48","slug":"sareptas-unusual-journey","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey","title":{"rendered":"Sarepta\u2019s Unusual Journey"},"content":{"rendered":"

Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta\u2019s Muscular dystrophy drug Eteplirsen, as its luck changed completely when the U.S. Food and Drug Administration on 19th<\/sup> September 2016 approved Sarepta Therapeutics’ Exondys 51 (eteplirsen) injection to treat patients with Duchenne muscular dystrophy (DMD). Exondys51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD. This is the first drug to get approved for this rare disease.<\/p>\n

Earlier in March, 2016, FDA had declared that it was not able to decide on Sarepta\u2019s eteplirsen and needed more time to review. In making this decision, FDA considered the potential risks associated with the drug, the life-threatening and debilitating nature of the disease for these children and the lack of available therapy. Under the accelerated approval provisions, FDA required Sarepta Therapeutics to conduct a clinical trial to confirm the drug\u2019s clinical benefit. In a complete turn of events, FDA approved Exondys 51 (eteplirsen) for the treatment of Duchenne muscular dystrophy (DMD), leading the stock to more than double in price in just a few days.<\/p>\n

Sarepta\u2019s drug has many health insurance providers are on board with it, others like Anthem Inc are still questioning whether it will do its customers any good \u2014 given the drug\u2019s accelerated approval. Additionally, on October 5, Sarepta Therapeutics and Summit Therapeutics partnered to advance the development of novel therapies for the treatment of Duchenne muscular dystrophy.<\/p>\n

Insight by:
\n<\/em>Sadaf Javed
\n<\/em>Associate Analyst
\n<\/em>DelveInsight Business Research<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta\u2019s Muscular dystrophy drug Eteplirsen, as its luck changed completely when the U.S. Food and Drug Administration on 19th September 2016 approved Sarepta Therapeutics’ Exondys 51 (eteplirsen) injection to treat patients with Duchenne muscular dystrophy (DMD). Exondys51 is specifically […]<\/p>\n","protected":false},"author":1,"featured_media":1375,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[218,624,625,626,593],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-1369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-duchenne-muscular-dystrophy-dmd","tag-exondys-51","tag-mutation","tag-sarepta","tag-us-food-and-drug-administration-fda","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nSarepta\u2019s Unusual Journey - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta\u2019s drug Eteplirsen\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta\u2019s Unusual Journey - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta\u2019s drug Eteplirsen\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-24T12:20:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T09:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09022513\/1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sarepta\u2019s Unusual Journey - DelveInsight Business Research","description":"Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta\u2019s drug Eteplirsen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey","og_locale":"en_US","og_type":"article","og_title":"Sarepta\u2019s Unusual Journey - DelveInsight Business Research","og_description":"Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta\u2019s drug Eteplirsen","og_url":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-10-24T12:20:25+00:00","article_modified_time":"2025-05-05T09:04:48+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09022513\/1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey","url":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey","name":"Sarepta\u2019s Unusual Journey - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09022513\/1.jpg","datePublished":"2016-10-24T12:20:25+00:00","dateModified":"2025-05-05T09:04:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta\u2019s drug Eteplirsen","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/sareptas-unusual-journey#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09022513\/1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09022513\/1.jpg","width":1024,"height":576,"caption":"Dominic Romito watches from a standing-room only crowd as hearings proceeded over conflicting interpretations of findings from Sarepta's clinical trial of an experimental drug to treat Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare disease that strikes one in 3500 boys who typically don't survive into their 30's. Sarepta's drug is meant to treat a specific gene mutation. (John Boal for The Boston Globe)"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/09022513\/1-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy (DMD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Exondys 51<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Mutation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sarepta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy (DMD)<\/span>","<span class=\"advgb-post-tax-term\">Exondys 51<\/span>","<span class=\"advgb-post-tax-term\">Mutation<\/span>","<span class=\"advgb-post-tax-term\">Sarepta<\/span>","<span class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Oct 24, 2016","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Oct 24, 2016 5:50 pm","modified":"Updated on May 5, 2025 2:34 pm"},"featured_img_caption":"Dominic Romito watches from a standing-room only crowd as hearings proceeded over conflicting interpretations of findings from Sarepta's clinical trial of an experimental drug to treat Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare disease that strikes one in 3500 boys who typically don't survive into their 30's. Sarepta's drug is meant to treat a specific gene mutation. (John Boal for The Boston Globe)","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1369"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1369\/revisions"}],"predecessor-version":[{"id":31634,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1369\/revisions\/31634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1375"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1369"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1369"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}